Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | Gross Profit |
0.00 | 0.00 | -77.00K | 0.00 | 0.00 | 0.00 | EBIT |
-56.79M | -69.64M | -42.26M | -21.57M | -7.28M | -5.18M | EBITDA |
-36.26M | 4.90M | -42.26M | 0.00 | -6.32M | 0.00 | Net Income Common Stockholders |
-51.32M | -64.73M | -41.47M | -21.47M | -13.60M | -5.63M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
114.21M | 107.30M | 96.06M | 58.55M | 4.07M | 5.60M | Total Assets |
121.26M | 138.74M | 102.56M | 65.32M | 4.23M | 5.70M | Total Debt |
0.00 | 0.00 | 53.00K | 0.00 | 0.00 | 728.00K | Net Debt |
-24.69M | -15.65M | -27.17M | -12.10M | -4.07M | -4.87M | Total Liabilities |
10.66M | 14.04M | 7.19M | 112.73M | 24.55M | 887.00K | Stockholders Equity |
110.60M | 124.70M | 95.37M | -47.41M | -20.32M | 4.81M |
Cash Flow | Free Cash Flow | ||||
-49.26M | -53.29M | -33.46M | -20.48M | -5.36M | -2.49M | Operating Cash Flow |
-49.26M | -53.29M | -33.46M | -20.48M | -5.36M | -2.49M | Investing Cash Flow |
54.59M | -43.28M | -21.77M | -50.02M | 0.00 | 0.00 | Financing Cash Flow |
372.00K | 84.99M | 70.36M | 78.53M | 3.84M | 8.08M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
48 Neutral | $6.84B | 1.02 | -53.11% | 2.50% | 16.84% | 0.92% | |
46 Neutral | $41.79M | 10.83 | -89.62% | ― | -71.68% | -397.61% | |
45 Neutral | $41.22M | ― | -139.16% | ― | 20.58% | 15.90% | |
43 Neutral | $40.93M | ― | -49.69% | ― | ― | 38.98% | |
42 Neutral | $43.42M | ― | -102.26% | ― | ― | 69.37% | |
34 Underperform | $43.57M | ― | 607.06% | ― | ― | 55.67% | |
28 Underperform | $43.06M | ― | <0.01% | ― | ― | -29.01% |
AN2 Therapeutics has promoted its Chief Legal Counsel, Joshua Eizen, to the roles of Chief Legal Officer and Chief Operating Officer, effective immediately. Eizen’s new compensation package includes a salary of $450,000, stock options, and restricted stock units that vest over time. This move is part of AN2’s strategic efforts to strengthen its leadership team, appealing to investors looking at executive management changes.